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ABSTRACT 
In an open clinical trial 20 patients of grade-I and grade-II uncomplicated Essential Hypertension of either 
sex aged between 25-70 years, were given Jatamamsi Churna in a dose of 10 grams per day in two equal 
divided doses for a duration of 60 days. At the end of trial period their systolic blood pressure was reduced 
from 148.9 mm of Hg to 132.6 mm of Hg and diastolic blood pressure was reduced from 97.1 mm of Hg to 
86.4 mm of Hg. Pulse pressure, mean blood pressure, and various clinical features were also significantly 
reduced after the therapy. No untoward effects were reported by any patient and their biochemical and 
Hematological parameters also remained within normal limits, both before and after the therapy. Thus trial 
drug i.e. Jatamamsi churna may prove an ideal drug for the management of grade-I and grade-II Essential 
Hypertension.  
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INTRODUCTION
 Hypertension is emerging as one of important 
public health problem in the developed as well as 
developing countries. In today’s competitive world and 
modern life style, anxiety, stress and strain are increasing 
alarmingly and influencing the development of various 
psychosomatic disorders including Hypertension. It is a 
major risk factor for the development of coronary artery 
disease, stroke, congestive heart failure and renal 
disorders[1]. Hypertension affects approximately one 
billion individual’s word wide. Recent data from 
Framingham Heart study suggest that individuals who are 
Normotensive at the age of 55 have a 90 percent life time 
risk for developing Hypertension[2]. 
 In clinical trials, Anti-Hypertensive therapy has 
been associated with reduction in stroke incidence 
averaging 35-40 percent; myocardial infarction 20-25 
percent, and heart failure, more than 50 percent[3]. Recent 
clinical trials have demonstrated that effective blood 
pressure control can be achieved in most patients who are 
Hypertensive, but the majority will require two or more 
Anti-Hypertensive drugs[4]. Presently a number of effective 
Anti-Hypertensive drugs are available but they are not free 
from untoward effects. Beta blockers can cause fatigue, 
cold extremities, Bradycardia, heart failure and 
Angiotensive converting enzyme inhibitors can cause 
cough, rash, and proteinuria etc. [5] An Anti-hypertensive 
drug should ideally improve patient’s compliance. Any 
treatment administered should be directed to not only 
control blood pressure, but also prevent target organ 
damage, thereby preserving cardiac and renal functions 
which increases patients life span. [6,7] One of the safest and 
potent anti-hypertensive drug from the reservoir is 
Jatamansi churna (Nardostachys jatamansi). It is used 
traditionally in the treatment of nervous headache, 
hypertension, epilepsy, intestinal colic, hysteria and 
depressive illness.8 More than 25 active principles have 
been isolated from the rhizome part of this plant which 
includes alkaloids jatamansone, nardostachone, 
jatamansicacid, coumarins, lignan, neolignans and 
sesquiterpenes.[9-10]. So still the quest for safe and ideal 
antihypertensive drug is there. So based on these facts we 
have made an effort to find a safe Anti-Hypertensive 
therapy through an Ayurvedic herbal formulation. The 
present clinical trial was conducted to evaluate the efficacy 
of Jatamamsi Churna[11] in the management of grade-I and 
grade-II essential hypertension. 
Inclusion Criteria 
 Twenty cases of grade-I and grade-II 
Hypertension between 25 to 75 years of age of either sex 
were included in the trial. Gradation of blood pressure was 
done on the basis of recommendations of Joint National 
Committee on Detection Evaluation and Treatment of High 
Blood Pressure i.e. JNC-7 as : 
Table 1: Gradation of blood pressure 
Category Systolic B.P. in 
mm of Hg 
Diastolic BP in 
mm of Hg 
Stage-I 140-159 90-99 
Stage-II >160 >100 
Exclusion Criteria  
 All the patients of secondary hypertension, 
patients having diastolic BP> 110 mm of Hg and systolic 
BP>180 mm of Hg, Hypertension associated with 
pregnancy and hypertension along with complications of 
target organs.  
Material and Methods 
Method of Study  
 Registered patients were given Jatamamsi Churna 
in a dose of 10 grams/day in two equal divided doses and 
advised it to make as decoction i.e., Kashaya with 5gms of 
Churna per dose for 60 days. Patients has been selected 
from OPD of Kayachikitsa Dept from Dr.BRKR Govt 
Ayurvedic College and Hospital, were thoroughly assessed 
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on the basis of various subjective and objective parameters 
after every 15 days till the completion of trial period i.e. 60 
days. However change in systolic, diastolic and mean blood 
pressure was the main criteria of assessment. Patients 
were also asked to report untoward effects if any, such as 
nausea, vomiting, giddiness, insomnia etc. Base line 
Haematological and Biochemical parameters including 
TLC, DLC, ESR, Hb, Fasting blood sugar, B. Urea, S. 
Creatinine, Lipid profile, Urine routine and microscopic 
examination were assessed both before and after therapy 
to observe the effects of trial drugs on other systems of the 
body. 
Observations and Results 
 Mean systolic blood pressure which was 148.9 
mm of Hg before treatment was reduced to 132.6 mm of 
Hg and mean diastolic blood pressure came down from 
97.1mm of Hg to 86 mm of Hg after 60 days of therapy. 
Reduction in both systolic and diastolic blood pressure 
was statistically highly significant (P<0.001). Effects of the 
therapy on mean blood pressure, pulse pressure and 
symptomatology are shown in Table No. 2 and 3 
respectively. Base line haematological and biochemical 
parameters at the beginning and end of the study did not 
show any abnormality (Table No. 4). 
Table 2: Effects of the Therapy on Blood Pressure 




SD + SE + T P 
15 days 30 days 45 days 
Systolic BP 148.9 141.1 135.6 133.8 132.6 10.94 12.9 2.8 5.73 <0.001 
Diastolic BP 97.1 94.7 88.6 86.6 86.4 11.01 10.18 2.27 4.69 <0.001 
Mean BP 113.8 110.6 100.06 98.1 96.2 15.42 25.9 5.7 2.21 <0.05 
Pulse Pressure 51.8 49.2 47 47.2 45.2 12.75 10.51 2.3 2.76 <0.05 
Table 3: Effects of the Therapy on Clinical Features 
Clinical Features Mean Score  % of relief SD + SE + T P 
BT AT      
Headache 1.7 0.45 73.52 0.824 0.184 5.69 <0.001 
Santapa 0.4 0.1 75 0.57 0.12 2.51 <0.005 
Padadaha 0.25 0.15 40 0.3 0.06 1.49 >0.05 
Krishta 1.55 0.2 87.09 0.933 0.20 6.75 <0.001 
Bhrama 0.85 0.15 82.15 0.732 0.16 4.27 <0.001 
Klama 1.1 0.2 81.81 0.55 0.12 7.2 <0.001 
Tamodarshana 0.3 0.1 66.66 0.52 0.11 1.78 >0.05 
Prabhuta mutrata 0.25 0.05 80 0.41 0.091 2.18 <0.05 
Krodha 0.75 0.2 73.33 0.604 0.13 4.07 <0.001 
Table 4: Effects of the Therapy on Biochemical Profile 
Variable in Mean Score % of relief  SD + SE + T P 
 BT AT 
S.Cholesterol 208 199.8 3.94 6.92 1.54 4.97 <0.001 
VLDL 30.35 29.2 3.78 0.98 0.22 5.2 <0.001 
LDL 112.5 110.95 1.42 1.56 0.34 4.5 <0.001 
HDL 58.9 57.3 2.71 2.68 0.6 5.3 <0.001 
S.Triglycerides 153.65 150.15 2.27 2.68 0.6 5.3 <0.001 
B.Urea 25.5 24.4 4.3 0.98 0.21 5.2 <0.001 
S.Creatinine 0.56 0.52 7.1 0.06 0.12 3.75 <0.001 
FBS 87.6 86.4 3.1 0.95 0.21 5.6 <0.001 
DISCUSSION 
 Hypertension is a multifactorial disease. Most of 
the patients of uncomplicated Hypertension remain 
asymptomatic during early years of the disease. A lot of 
Anti-Hypertensive drugs are available today but none of 
them possess curative potential. Because all the currently 
available drugs have just palliative effect hence they are 
required to be taken throughout the life. Due to this reason 
untoward effects associated with presently available drugs 
are inevitable. Recent clinical trials have demonstrated 
that majority of the Hypertensive patients require multiple 
antihypertensive drugs for optimum blood pressure 
control.[4] Due to prolonged multiple drug therapy 
annoying untoward effects are further augmented, leading 
to decreased compliance in asymptomatic patients. So still 
the quest for an ideal and safe Anti-Hypertensive drug is 
there. Present trial is an attempt to develop an ideal herbal 
Anti-Hypertensive drug which is potent and safe for long 
term use. 
 In this study the trial drug fulfilled all the lacunae 
mentioned above, as it significantly reduced systolic blood 
pressure by 16.3 mm of Hg, diastolic blood pressure by 
10.7 mm of Hg. Pulse pressure and mean blood pressure 
were also statistically significantly lowered by 6.6 mm of 
Hg and 17.6 mm of Hg respectively. Various clinical 
features except Padadaha and Tamodarshana were also 
significantly improved after the therapy (Table No. 3). 
Hypertension accelerates the development of 
Atherosclerosis, especially when combined with other risk 
factors such as Dyslipidaemia. After therapy, there was 
marginal reduction in serum total cholesterol, VLDL and 
triglycerides. (Table No. 4) 
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 Animal experimentation has proved the Anti-
Hypertensive activity of Jatamamsi. Pharmacological 
studies have also revealed its central depressant action 
and vascular smooth muscle relaxation properties. So 
probably Anti-Hypertensive action of Jatamamsi is 
mediated partly through reduction in cardiac output and 
partly through reduction in peripheral resistance. During 
the course of treatment all the patients reported a growing 
feeling of well being and none of them reported any 
untoward effect. 
CONCLUSIONS 
 Optimum blood pressure control is desirable to 
reduce long term cardiovascular mortality and morbidity. 
The trial drug i.e. Jatamamsi Churna can be an effective and 
ideal Anti-Hypertension drug in grade-I and grade-II 
essential Hypertension at the prescribed doses. It can be 
more useful in the management of essential Hypertension 
with associated dyslipidemia. It has been found to be free 
from any untoward effects. More studies are desperately 
required for thorough assessment of Anti-Hypertensive 
potential of trial drug i.e. Jatamamsi. 
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